Get 20% Off Journals at LWW.com

Economic Burden of Metastatic Clear-Cell Renal Cell Carcinoma for French Patients Treated With Targeted Therapies.

Clin Genitourin Cancer 2019 Feb 7;17(1):e227-e234. Epub 2018 Nov 7.

Department of Pharmacy, University Hospital, Besançon, France; INSERM, EFS BFC, UMR1098, Interactions hôte-greffon-tumeur, Ingénierie Cellulaire et Génique, University Bourgogne Franche-Comté, Besançon, France. Electronic address:

Background: Targeted therapies have transformed the treatment of metastatic clear-cell renal cell carcinoma (mccRCC). Despite the importance of mccRCC, studies on its economic burden in daily practice are sparse. The purpose of this retrospective study was to evaluate cost of illness for 224 patients with mccRCC included in the cohort published by Thiery-Vuillemin et al (Factors influencing overall survival for patients with metastatic clear-cell renal cell-carcinoma in daily practice. Clin Genitourin Cancer 2018; 16:e297-305), and then to determine the explanatory factors of cost of illness.

Patients And Methods: The study was performed from the French Public Healthcare System perspective with lifetime horizon. Only direct medical costs were included. Multiple linear regression was used to search for explanatory factors of cost of illness. The robustness of results was assessed.

Results: The mean cost of illness was estimated at €71,185 ± 52,683. Outpatient/inpatient treatment and hospitalization represented 76.0% and 19.7% of this cost, respectively. After adjustment, 5 explanatory factors were identified: time of disease control for the metastatic first-line treatment ≥6 months, number of lines of treatment >2, nephrectomy at metastatic stage, lack of metastases at presentation, and age at metastatic diagnosis younger than 65 years. Individually, they increased cost of illness by 128%, 95%, 53%, 53%, and 23%, respectively.

Conclusion: Although it is difficult to transpose our economic evaluation results to those obtained in other countries, it should be noted that our findings were consistent with them and robust. To our knowledge, our study was the first to accurately identify explanatory factors of cost of illness. Identifying them could enable us to predict the budgetary effect on a regional level of managing patients who began their first-line treatment with a targeted therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.10.016DOI Listing
February 2019
Save 15% Survey

Similar Publications

Effectiveness of enhancing cognitive reserve in children, adolescents and young adults at genetic risk for psychosis: study protocol for a randomized controlled trial.

Rev Psiquiatr Salud Ment 2021 Feb 22. Epub 2021 Feb 22.

Centro de Investigación biomédica en Red de Salud Mental (CIBERSAM), Spain; Barcelona Bipolar and Depressive Unit, Institute of Neurosciences, University of Barcelona, IDIBAPS, Barcelona, Catalonia, Spain.

Background: Offspring of patients diagnosed with Bipolar Disorder and Schizophrenia (Off-BDSZ) have a high genetic risk of developing a mental illness. The aim of this project is to develop and investigate the efficacy of an intervention aimed at this population, based on the concept of cognitive reserve.

Methods: This is a multicenter randomized trial with an experimental test-retest design study with control group. Read More

View Article and Full-Text PDF
February 2021

Estimated Medicaid Costs Associated with Hepatitis A During an Outbreak - West Virginia, 2018-2019.

MMWR Morb Mortal Wkly Rep 2021 Feb 26;70(8):269-272. Epub 2021 Feb 26.

Hepatitis A is a vaccine-preventable disease caused by the hepatitis A virus (HAV). Transmission of the virus most commonly occurs through the fecal-oral route after close contact with an infected person. Widespread outbreaks of hepatitis A among persons who use illicit drugs (injection and noninjection drugs) have increased in recent years (1). Read More

View Article and Full-Text PDF
February 2021

Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study.

Expert Rev Pharmacoecon Outcomes Res 2021 Feb 25. Epub 2021 Feb 25.

- Department of Health Economics, Corvinus University of Budapest, 8 Fővám tér, H-1093, Budapest, Hungary.

: Hidradenitis suppurativa (HS) is a potentially disabling, chronic inflammatory skin disease affecting up to 1% of the population in Europe. This study aims to assess the cost-of-illness of HS from a societal perspective in Hungary, and to analyse the predictors of costs.: A multicentre, cross-sectional cost-of-illness study was performed among 200 adult HS patients. Read More

View Article and Full-Text PDF
February 2021

Optimising care pathways for adult anorexia nervosa. What is the evidence to guide the provision of high-quality, cost-effective services?

Eur Eat Disord Rev 2021 Feb 24. Epub 2021 Feb 24.

Department of Psychiatry, University Hospital of Bellvitge-IDIBELL and CIBERobn, Barcelona, Spain.

The aim of this paper is to consider how changes in service planning and delivery might improve the care pathways for adult anorexia nervosa. Although anorexia nervosa has a long history in Europe, its framing as a mental disorder is quite recent. The changing forms and increasing epidemiology of eating disorders has led to the expansion of specialised services. Read More

View Article and Full-Text PDF
February 2021

Hospitals' Diversity of Diagnosis Groups and Associated Costs of Care.

Pediatrics 2021 Feb 24. Epub 2021 Feb 24.

Children's Hospital Association, Lenexa, Kansas.

Background And Objectives: Hospitals treating patients with greater diagnosis diversity may have higher fixed and overhead costs. We assessed the relationship between hospitals' diagnosis diversity and cost per hospitalization for children.

Methods: Retrospective analysis of 1 654 869 all-condition hospitalizations for children ages 0 to 21 years from 2816 hospitals in the Kids' Inpatient Database 2016. Read More

View Article and Full-Text PDF
February 2021